Opthea's Pivotal Phase 3 Trials For Sozinibercept In Wet AMD Completes Enrollment, Topline Results Anticipated Mid-2025
- Phase 3 program enrolled 1,984 patients across COAST and ShORe trials
- Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b
- Topline data from both pivotal trials expected in mid-CY2025